Wednesday, 25th of July 2012 |
L. Newman1, L. Ben-Youssef1, A. Gatuguta2, A. Njoroge3, M. Merkel1, Q. Ton1, D. Wamalwa3, B. Payne1, C. Farquhar1
1University of Washington, Seattle, United States, 2Kenyatta University, Nairobi, Kenya, 3University of Nairobi, Nairobi, Kenya
Also accessible at http://pag.aids2012.org/abstracts.aspx?aid=18697
Background: The HIV epidemic has the potential to exacerbate measles morbidity and mortality, as HIV reduces both initial and sustained responses to measles vaccination. Studies have suggested that highly active antiretroviral treatment (HAART) is unable to restore measles immune responses in HIV-infected children who had been previously vaccinated. To establish guidelines for re-vaccination, it is essential to determine whether there is sustained protection against measles in HIV-infected children on HAART.
Methods: A prospective cohort study based at Kenyatta National Hospital in Nairobi enrolled HIV-infected children on HAART with a CD4%>15. Caregivers were interviewed and blood was obtained from children for measles antibody, CD4%, and complete blood count measures. Measles IgG antibody status was determined using ELISA (Siemans, USA). Correlates of positive antibody responses were determined using independent t-tests and multivariate logistic regression. Equivocal measles antibody results were classified as negative.
Results: All ninety-eight HIV-infected children reported measles vaccination before age 12 months. Mean time on HAART was 3.5 years (range 0.5-12.5), mean age was 6.5 years (range 1.1-11.1), and 48 (49%) were male at enrolment. Forty (41%) of the 98 children had positive measles IgG results, 40 (41%) were negative, and 18 (18%) had equivocal results. Children under age 6 were more likely to have protective measles antibody (OR=2.53, 95%CI 1.05-6.12, p-value=0.039). There was no statistically significant association between CD4% or gender and a positive result, though the median CD4% was higher, and more females than males had protective antibody titers (34% vs. 31%; 60% vs. 45%, respectively). Time on HAART was not associated with antibody results.
Conclusions: Among HIV-infected Kenyan children with immune reconstitution on HAART, only 41% had protective levels of measles antibody at baseline. Continued follow-up for 2 years after these children are re-vaccinated will determine optimal timing and immunization guidelines for HIV-infected children on HAART.
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
41212638 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |